ASTRAZENECA'S FARXIGA SCORES A SPEEDY FDA REVIEW IN KIDNEY DISEASE—AND GETS ANOTHER JUMP ON RIVAL JARDIANCE

Pushing for a new approval for SGLT2 med Farxiga in chronic kidney disease (CKD), AstraZeneca last year posted impressive data in its pivotal trial. Now, the FDA has accepted its CKD application and awarded a priority review, setting up a decision for the second quarter—and putting Farxiga even farther ahead of its would-be rivals.
Read more...

;